Patient preferences for drug therapy in inflammatory arthritis: protocol for a living systematic review and evidence map to inform clinical practice guidelines
Rachelle Buchbinder,
Peter Tugwell,
Pablo Alonso-Coello,
Mickael Hiligsmann,
Nick Bansback,
Laurie Proulx,
Dawn P Richards,
Wojtek Wiercioch,
Glen Hazlewood,
Samuel Whittle,
Jordi Pardo Pardo,
Marie Falahee,
Holger Schünemann,
Robby Nieuwlaat,
Pakeezah Saadat,
Simon Kuper
Affiliations
Rachelle Buchbinder
9 Musculoskeletal Health and Wiser Health Care Units, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
Peter Tugwell
7 Department of Medicine, University of Ottawa Faculty of Medicine, Ottawa, Ontario, Canada
Pablo Alonso-Coello
16 Centro GRADE Barcelona, Instituto de Investigacion Biomedica, Barcelona, Spain
Mickael Hiligsmann
6 Department of Health Services Research, CAPHRI Care and Public Health research Institute, Maastricht University, Maastricht, Netherlands
Nick Bansback
2 School of Population and Public Health, The University of British Columbia, Vancouver, British Columbia, Canada
Laurie Proulx
12 Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada
Dawn P Richards
12 Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada
Wojtek Wiercioch
14 Department of Medicine, McMaster University, Hamilton, Ontario, Canada
Glen Hazlewood
22 McCaig Institute for Bone and Joint Health, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
Samuel Whittle
10 School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
Jordi Pardo Pardo
20 Cochrane Musculoskeletal, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
Marie Falahee
4 Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
Holger Schünemann
13 Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
Robby Nieuwlaat
14 Department of Medicine, McMaster University, Hamilton, Ontario, Canada
Pakeezah Saadat
1 Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada
Simon Kuper
19 Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, Limburg, Netherlands
Introduction The pharmacological management of inflammatory arthritis often requires choices that involve trade-offs between benefits, risks and other attributes such as administration route, frequency and cost. This living systematic review aims to inform international clinical guidelines on inflammatory arthritis by creating an evidence map of patient preference studies concerning the trade-offs in pharmacological management of inflammatory arthritis.Methods and analysis We will include published and peer-reviewed full-text studies in any language that quantitatively assess preferences of patients for the pharmacological management of inflammatory arthritis (rheumatoid arthritis, spondyloarthritis and juvenile idiopathic arthritis). Studies must use either stated or revealed preference methods to assess preferences and provide a quantitative assessment of relevant characteristics, such as benefits, risks, costs and process attributes. Articles will identified through Medline and EMBASE database searches from inception using search terms that combine keywords and subject headings for inflammatory arthritis and preference-based methods, and a search in the Health Preference Study and Technology Registry using keywords for the populations of interest. Two independent reviewers will perform abstract and full-text screening. Risk of bias will be assessed using the GRADE risk of bias tool. An evidence map will be generated to summarise included studies and their assessments of each trade-off. The search will be conducted every 6 months with new studies added to the inventory.Ethics and dissemination Ethics approval is not required. Results from the base review will be published in a peer-reviewed journal and findings will be presented at conferences. In the living model, we will publish updates and datasets on an Open Science Framework page, with periodic updates in peer-reviewed journals.
